Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 23:9:936613.
doi: 10.3389/fsurg.2022.936613. eCollection 2022.

Histological regression of peritoneal metastases of recurrent tubo-ovarian cancer after systemic chemotherapy

Affiliations

Histological regression of peritoneal metastases of recurrent tubo-ovarian cancer after systemic chemotherapy

Basile Pache et al. Front Surg. .

Erratum in

Abstract

Introduction: Post-treatment histological regression of peritoneal metastases (PM) is a new and potentially important predictor of oncological outcomes. Histology of PM from adnexal origin is usually evaluated by the Chemotherapy Response Score (CRS). The aim of this preliminary study was to quantify the response of PM of recurrent tubo-ovarian cancer (TOVC) after systemic chemotherapy by using the recently validated Peritoneal Regression Grading System (PRGS) and compare it with CRS. Correlation with per operative evaluation through Peritoneal Cancer Index (PCI) was performed.

Material and methods: Retrospective cohort study of all consecutive patients with recurrent PM from TOVC undergoing surgery after prior systemic chemotherapy from January 2015 to March 2019. Biopsies were assessed with the four-scale PRGS.

Results: Thirty-eight patients were included. Patients had a median of 2 (range 1-2) lines and 12 (range 3-18) cycles of prior systemic chemotherapy. Overall mean (SD) PRGS was 2.3 (±1.1). Of the patients, 26% (10) had complete response (PRGS 1), 40% (15) had major response (PRGS 2), 26% (10) minor response (PRGS 3), and 8% (3) had no response (PRGS 4). Mean PRGS was positively correlated with the Peritoneal Cancer Index (ρ = 0.5302, p = 0.0003) and inversely correlated with CRS (ρ = -0.8403, p < 0.0001). No correlation was highlighted between mean PRGS and overall survival (ρ = -0.0195, p = 0.9073).

Conclusion: CRS and mean PRGS correlated with each other. Histological response of PM after systemic chemotherapy was quantifiable and variable. The role of PRGS for the evaluation of treatment response and as potential surrogate marker for oncological outcomes is part of ongoing and planned research.

Keywords: PRGS; chemotherapy; gynecology; histology; ovary; peritoneal metastasis; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Sensitivity analysis of histological regression (PRGS) of peritoneal cancer after systemic chemotherapy. Horizontal box plots with illustration of highest, lowest, medians, and outliers Peritoneal Regression Grading System (PRGS) response stratified by PCI, lines and cycles of chemotherapies. PRGS-1 corresponds to a complete regression with absence of tumor cells; PRGS-2 to major regression features with only a few residual tumor cells; PRGS-3 to minor regression with predominance of residual tumor cells and only few regressive features; PRGS-4 to no response. PRGS: median, 10th, and 90th percentiles with outlier's data.
Figure 2
Figure 2
Peritoneal Regression Grading System (PRGS) was plotted against the extent of peritoneal disease [measured by the Peritoneal Cancer Index (PCI)] without regard to systemic chemotherapy regimen. ρ =0.5583, p = 0.0003.
Figure 3
Figure 3
Peritoneal Regression Grading System (PRGS) and Chemotherapy Response Score (CRS) correlation. ρ =−0.8403, p < 0.0001.

Similar articles

References

    1. Burg L, Timmermans M, van der Aa M, Boll D, Rovers K, de Hingh I, et al. Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands. J Gynecol Oncol. (2020) 31(5):e58. 10.3802/jgo.2020.31.e58 - DOI - PMC - PubMed
    1. Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract. (2012) 2012:541842. 10.1155/2012/541842 - DOI - PMC - PubMed
    1. Mancari R, Cutillo G, Bruno V, Vincenzoni C, Mancini E, Baiocco E, et al. Development of new medical treatment for epithelial ovarian cancer recurrence. Gland Surg. (2020) 9(4):1149–63. 10.21037/gs-20-413 - DOI - PMC - PubMed
    1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. (2006) 6(8):583–92. 10.1038/nrc1893 - DOI - PubMed
    1. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer. (2009) 45(2):290–9. 10.1016/j.ejca.2008.10.030 - DOI - PMC - PubMed

Grants and funding

The research did not receive specific funding, but was performed as part of the employment of the authors, at the Lausanne University Hospital (CHUV), Switzerland. Open access funding was provided by the University of Lausanne.